Cantor Fitzgerald Downgrades Gossamer Bio (GOSS) to Neutral

Gossamer Bio, Inc. (NASDAQ:GOSS) is 1 of the

8 Most Oversold Penny Stocks to Buy Right Now.

On March 23, 2026, Cantor Fitzgerald downgraded Gossamer Bio, Inc. (NASDAQ:GOSS) to Neutral from Overweight without a terms target. Cantor Fitzgerald cited the antagonistic Phase 3 PROSERA readout and an unclear regulatory way for seralutinib successful pulmonary arterial hypertension, noting it is hard to person condemnation connected a way to commercialization.

On March 17, 2026, Gossamer Bio reported Q4 EPS of (21c), compared to the (20c) statement estimate, with gross of $13.799M versus $7.52M consensus. CEO Faheem Hasnain said the institution is focused connected reviewing the PROSERA dataset, engaging with the FDA, and evaluating strategical options, noting the proceedings “narrowly missed” its superior endpoint but that the information enactment seralutinib arsenic an progressive cause successful PAH, peculiarly successful much precocious patients.

Earlier successful March, H.C. Wainwright lowered its terms people connected Gossamer Bio to $5 from $10 and maintained a Buy rating, reducing its probability of occurrence for seralutinib successful pulmonary arterial hypertension to 50% from 70%.

Gossamer Bio, Inc. (NASDAQ:GOSS) develops seralutinib for the attraction of pulmonary hypertension and pulmonary arterial hypertension.

While we admit the imaginable of GOSS arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey connected Google News.